Finerenone
- CAS No.
- 1050477-31-0
- Chemical Name:
- Finerenone
- Synonyms
- Finerenone;BAY 94-8862;(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;Finerone;Finerenone (BAY 94-8862);BAY948862;Fenaridone;Fenalidone;Non Nilidone;D5-Finerenone
- CBNumber:
- CB72744895
- Molecular Formula:
- C21H22N4O3
- Molecular Weight:
- 378.42
- MDL Number:
- MFCD29047135
- MOL File:
- 1050477-31-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Boiling point | 554.7±50.0 °C(Predicted) |
|---|---|
| Density | 1.29±0.1 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol |
| pka | 14.76±0.40(Predicted) |
| form | solid |
| color | White to off-white |
| λmax | 255 nm |
| InChI | InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1 |
| InChIKey | BTBHLEZXCOBLCY-QGZVFWFLSA-N |
| SMILES | N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C |
| FDA UNII | DE2O63YV8R |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS08,GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H360-H301 | |||||||||
| Precautionary statements | P264-P270-P301+P310-P321-P330-P405-P501 | |||||||||
| NFPA 704 |
|
Finerenone price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 36086 | Finerenone ≥98% | 1050477-31-0 | 5mg | $110 | 2026-04-30 | Buy |
| Cayman Chemical | 36086 | Finerenone ≥98% | 1050477-31-0 | 10mg | $209 | 2026-04-30 | Buy |
| Cayman Chemical | 36086 | Finerenone ≥98% | 1050477-31-0 | 25mg | $304 | 2026-04-30 | Buy |
| Cayman Chemical | 36086 | Finerenone ≥98% | 1050477-31-0 | 50mg | $550 | 2026-04-30 | Buy |
| Biosynth | FF180916 | Finerenone | 1050477-31-0 | 0.025g | $220 | 2026-06-04 | Buy |
Finerenone Chemical Properties, Uses, Production
Description
Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.
Uses
Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used for the treatment of diabetic nephropathy, chronic kidney disease and end-stage renal disease. It can reduce the proteinuria of patients and improve the glomerular filtration rate.
Indications
Finerenone is used for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Finerenone's indication is to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage renal disease, end-stage renal disease, cardiovascular death, non-fatal myocardial infarction, and risk of hospitalisation for heart failure.
brand name
Finerenone is sold under the brand name Kerendia and Firialta.
Biological Activity
Finerenone (FIN, BAY 94-8862) is a highly selective, orally active, nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease.
Synthesis
Synthesis scheme of finerenone: Firstly, benzaldehyde 20.1 was condensed with acetoacetamide under Knoevenagel condensation conditions to give high yield of ketone 20.2 of undetermined structure.Meanwhile, pyridinyl chloride 20.3 was treated at high temperature with strong alkali conditions followed by treatment with strong acid at low temperature to give filterable pyridinone solid 20.4.
Addition of 20.2 to a heated isobutanol solution of 20.4 resulted in a condensation-cyclisation reaction to give the nitrogen-containing heterocyclic compound 20.5 in good yield. The conversion of the pyridone to the corresponding ether was achieved by treating the pyridone with 1,1,1-triethoxyethane under acidic conditions. Some of the synthetic methods for fenaridones were carried out by chromatographic separation of the racemate 20.6, while a recent patent reports a classical splitting using tartaric acid derived salts. In one example, 20.6 was reacted with p-toluoyl-d-tartaric acid in a mixture of ethanol and water to give the target enantiomer in 78% enantiomeric excess, which was purified to 99% enantiomeric excess by re-suspension in ethanol and water to ultimately give 20.7 in about 41% yield. Adjusting the pH in water and ethanol with sodium carbonate gave the free base of fenaridone (20) in 97% yield.
in vivo
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Frmter (MWF) rat.
Mode of action
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney.
References
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI: 10.1159/000516213
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Finerenone Preparation Products And Raw materials
Raw materials
Preparation Products
Finerenone Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shandong Shining Pharm Co.,Ltd | 18866891188 18866891188 | zhaojiangxia@shiningpharm.com | China | 203 | 58 |
| Hubei Tianshu Pharmaceutical Co., Ltd | 025-58741518 13327727315 | yao_dongyuan@vcarepharmatech.com | China | 19 | 58 |
| Hangzhou Chemtrue Bio-Tech Co.,Ltd. | 19967494293 | sales@chemtrue-bio.com | China | 303 | 58 |
| Beijing Mesochem Technology Co., Ltd. | 010-57862036 18811083386; | msales@mesochem.com | China | 209 | 58 |
| Nanjing Vcare PharmaTech Co., Ltd | 025-58741518 13327700685 | sales@vcarepharmatech.com | China | 483 | 58 |
| Shandong Sihuan Pharmaceutical Co., Ltd. | 0531-88993893 13335127975 | fairouz@sdsihuanpharm.com | China | 79 | 58 |
| Allikang Pharmaceutical Co., LTD | 0573-87390950 13806705416 | wzj@alicornpharma.com | China | 58 | 58 |
| CHANGZHOU PHARMACEUTICAL FACTORY | 0519-88821493 18915891730 | shm@czpharma.com | China | 176 | 58 |
| Jinan XinKe Pharmaceutical Technology Co., Ltd. | 0531-88259693 18660188356 | 2820602043@qq.com | China | 78 | 58 |
| Shandong Haiyou Furuida Pharmaceutical Co., Ltd. | 0531-81213160 18369049521 | 244846234@qq.com | China | 30 | 58 |
Related articles
- Finerenone: Synthesis and Introduction
- Finerenon, or BAY94- 8862, is a non-steroidal mineralocorticoid receptor (MR) antagonist approved by the USFDA in July 2021 an....
- Jan 18,2024
- Side effects of Finerenone in the treatment of diabetic nephropathy
- Finerenone is a novel non-steroidal, highly selective salicorticoid receptor antagonist (MRA) with high binding affinity, high....
- Nov 21,2023
View Latest Price from Finerenone manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-20 | Finerenone
1050477-31-0
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | ||
 |
2026-09-03 | Finerenone
1050477-31-0
|
1kg | ＞99% by HPLC | 10kg/month | Zison Pharmaceutical (Shandong) Co., Ltd. | ||
 |
2026-08-25 | Finerenone
1050477-31-0
|
$85.00-850.00 | 10kg | 0.99 | 20tons | Zibo Hangyu Biotechnology Development Co., Ltd |
-
- Finerenone
1050477-31-0
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
-
- Finerenone
1050477-31-0
- ＞99% by HPLC
- Zison Pharmaceutical (Shandong) Co., Ltd.
-
- Finerenone
1050477-31-0
- $85.00-850.00
- 0.99
- Zibo Hangyu Biotechnology Development Co., Ltd
1050477-31-0 (Finerenone) Related Search:
1of2
